Tuberous sclerosis complex (TSC), an autosomal-dominant disorder caused by the constitutive activation of mammalian target of rapamycin (mTOR), gives rise to hamartomas in multiple organs. Angiofibromas are the most predominant skin lesions observed in patients with TSC older than 5 years
1-3 and characteristically consist of numerous pink to reddish papules or nodules that are typically located on the cheeks, nose, and chin. Most patients also develop plaques, hypomelanotic macules, ungual fibromas, and/or shagreen patches.
3,4 These skin lesions are permanent, cause appearance concerns that considerably impair patient quality of life, and have been treated by invasive therapeutic modalities (eg, surgery and laser therapy) that are associated with a high risk for complications and sequelae.
2 However, clinical outcomes of these treatments have been unsatisfactory due to the frequent recurrence of the lesions. Moreover, an invasive treatment may be difficult to administer in patients with extensive angiofibromas or severe intellectual impairment. In consequence, these patients frequently remain untreated even though they could benefit from a safe and effective therapy that is easy to administer.